7 studies on Gh secretagogue mechanism curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
This study provides evidence that activating the `GHSR` to enhance the body's natural, pulsatile GH release pattern is a viable strategy for managing obesity and its metabolic complications. For individuals exploring …
**Clinicians and biohackers using sermorelin or GHRP-2** should recognize that abdominal fat is the dominant suppressor of combined secretagogue synergy — not simply age or low testosterone. **Reducing AVF before or a…
**Clinicians and peptide users targeting GH optimization cannot rely on testosterone normalization alone** to restore somatotropic function — AVF and IGF-I levels are independent, dominant modulators. For practitioner…
This study establishes that MK-0677 is effective at raising IGF-1 levels in the specific, vulnerable population of hemodialysis patients, a group where anabolic support is critically needed to combat protein-energy wa…
**The quantified SC50 of 214 nmol/L gives clinicians and researchers a concrete pharmacological benchmark** for designing ipamorelin dosing regimens — doses that push plasma concentrations well above this threshold sh…
**The practical takeaway for clinicians and researchers is that GHS peptides ipamorelin and GHRP-6 stimulate bone growth in adult female rats, but the mechanism is periosteal/dimensional expansion rather than increase…
**CJC-1295's ability to bioconjugate to endogenous albumin in vivo after a single subcutaneous dose** fundamentally changes the pharmacokinetic calculus for GRF-based therapies — a single injection may sustain GH axis…